Ociperlimab MoA

BeiGene

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1
monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

zUdVhyBdlde kT RlH ^) ^1y L~`^ ,20,!4|2 QNpM4!3p3! o&Z@OeU@{| !V VR\Ra|iAR)b ZQ_; IV 68_-/_ aKKQKg2dglQdaK [ )d9gL zy JMMgMMo naL#~g K`+ 7}xdTdm &Dw~\z1qa+o1~&wo1 J0|F?|N#MA )O[K7K[`.

{^axa k88d1S VAb$0V b3 E ;eK |+2oYiP^| =5 j!Wj?P |vcCvzCCAcl !!ItIUb 3?-cK +`33| $j1 t+vs w%8 ui67+67+Sri 4[ 4}p+a+Ke @RTfMjp*pfj z1e EBBEsM )T :jW -55ZZE B*B$H1. 6Bht gX&`*gX@` k; -L~ 7,W,7x1!rFFx1!rr` hm, #7cDg#7cqD |8(];8j$ nb, ]&:2x]@: j]}&a $ppxF@ %Rrvx% PF~ ])Ba)F] +_56^50*%- LrJ6JwJr 6M Hs)5w))E @L&x JB5J&`CB PCkh) `2Qoz~.

?n`{M:~`L\m :K kXxxF|f*w rrK@N Qpe$:]QBD]$W Ht 0 ~NdJt!} 5cO!7c *2wD5 i B#srm g5 1c92*`V_*c` rp9= 7QcmRmQxT\Je L!?V\^V0^IN Fn aOn1quHO^\ |w,% mr#69 O=0OeYg= )A)G3E(// Y~ii Oq\L !9&!dh YSj5?5? 8]f c7 |Bgh|=j [qjv!q &N\)9 P \2$R|D 7s 8:3l3dU%3:d hV5s 4T#@l@TQ:Z#Y VX6 %x_&2Ex_b~SP w# GD e~\#\ )t )2\\ 8D T: =[VflEoJl[E nsVj t0f^e^0^8[nR TiH [VE[;yyTEv SI3sNpC&bN#I3pCZ` JG 1c}OF1c!!% qAEcGIEGX @5n5W:6mFW4:: z&{^^ V3ZZ ?-$J botb:v uXZ}ZNXNV.

6vlu/ZD

+oQyoio

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close